Keep Childhood Cancer Away®

If you have just been told

Nothing you did caused this. Childhood cancer is not caused by anything a parent did or failed to do — not diet, not screen time, not vaccines, not stress, not power lines, not something missed at a check-up. Most childhood cancers arise from random errors in cell division during growth. The guilt is close to universal among parents and it is not warranted.

Two practical things matter enormously in the first week:

1. Treatment at a children's cancer centre. Paediatric oncology is highly centralised for good reason — outcomes are better, and most children are treated on a standardised protocol refined over decades of collaborative trials.

2. Ask about a clinical trial, and about fertility preservation, before treatment starts. A large share of children are treated on trials, and that is a mark of good care rather than experimentation. Fertility preservation is time-critical and easily missed in the rush — ask on day one even if it feels absurdly premature.

The main childhood cancers

Who is at risk

• For the great majority, no cause is ever found. Childhood cancers are largely not linked to lifestyle or environment in the way adult cancers often are.
• Inherited predisposition accounts for roughly 10% — Li-Fraumeni, hereditary retinoblastoma, neurofibromatosis, Beckwith-Wiedemann, DICER1, Down syndrome (which raises leukemia risk).
• Previous cancer treatment — chemotherapy or radiation for an earlier cancer can rarely cause a second one years later.
• High-dose radiation exposure. Diagnostic X-rays and routine imaging are not established causes at ordinary doses.
• A very small number are linked to infections or immune deficiency.
• Not causes: vaccines, diet, mobile phones, power lines, injury, or anything a parent did during pregnancy or afterwards.

Finding it early

There is no population screening for childhood cancer — it is far too rare, and screening healthy children would cause more harm than good. Children with known genetic predisposition syndromes are the exception and are surveilled on specific schedules.

Symptoms worth acting on — nearly all of these are far more often something ordinary, and that is exactly why persistence is the signal:

• Unexplained persistent pallor, bruising or bleeding, or petechiae (pinprick red spots).
• Persistent unexplained fever, or repeated infections.
• Bone or joint pain that wakes a child at night, or an unexplained limp.
• A lump or swelling anywhere, particularly if firm, painless and growing.
• Morning headaches with vomiting, unsteadiness, squint, or a change in behaviour or school performance.
• A white reflection in the pupil in photographs, or a new squint — this needs same-week eye assessment.
• Unexplained weight loss, drenching night sweats, or a swollen abdomen.

Trust persistence, and trust yourself. If something has not resolved and your instinct says it is not right, ask again and ask for a blood test or imaging. Parents who return a second and third time are not being difficult; they are frequently the reason a diagnosis is made.

How it’s diagnosed

Depends on the cancer: blood counts and a bone marrow biopsy for leukemia; MRI for brain tumours; ultrasound, CT or MRI plus biopsy for solid tumours. Sedation or general anaesthetic is used for scans and procedures in young children.

Molecular and genetic testing is now central in paediatric oncology — it refines the diagnosis, assigns risk group, and opens targeted treatment. Ask what testing is being done and when results are expected.

Ask about a germline genetic evaluation too. Around one in ten childhood cancers involves an inherited predisposition, and knowing changes surveillance for your child and potentially for siblings.

Staging and risk groups

Childhood cancers mostly do not use the adult TNM system. Each disease has its own framework, and what your team will talk about is usually a risk group rather than a stage:

• Leukemia — standard, high or very high risk, based on age, white cell count, genetics and how quickly the marrow clears in the first weeks.
• Neuroblastoma — low, intermediate or high risk (INRG), incorporating age, MYCN amplification and imaging features. Some low-risk tumours are observed and regress without treatment.
• Wilms tumour — stage I–V plus favourable or unfavourable histology.
• Brain tumours — graded and classified molecularly rather than staged.
• Sarcomas — grouped by site, size, resectability and spread.

Response to early treatment is itself part of the risk assignment in several of these — which is why the plan can change a few weeks in, and why that change is not necessarily bad news.

Biology and why protocols matter

Childhood cancers are biologically different from adult ones. They arise from developing tissue rather than from decades of accumulated damage, they carry far fewer mutations, and they are generally much more sensitive to chemotherapy and radiation — which is precisely why they are so often curable.

That sensitivity cuts both ways: growing tissue is also more vulnerable to long-term harm from treatment, which shapes every decision below.

Treatment follows collaborative protocols developed through decades of international trials. If your child is offered a trial, that is standard practice in paediatric oncology and a major reason survival improved from 63% to 85%.

How it’s treated

Chemotherapy is the backbone of most childhood cancer treatment, often over months to years — ALL treatment typically runs two to three years, most of it as an outpatient.

Surgery for solid tumours, frequently after chemotherapy has shrunk them.

Radiation is used more sparingly in children than in adults, and deliberately so. A developing brain, spine, breast or gonad is far more vulnerable to long-term effects. When radiation is needed, technique is chosen to protect the future: proton therapy is particularly valuable in children because it deposits little dose beyond the target, sparing growing tissue and reducing second-cancer risk. Dr. Hess trained as a paediatric proton therapy fellow at Massachusetts General Hospital, and this is exactly the trade-off that work is about.

Immunotherapy and CAR T-cell therapy have transformed relapsed ALL and are used in neuroblastoma. Stem cell transplant for high-risk disease.

Supportive care is treatment, not an add-on — infection prevention, nutrition, pain control, school liaison, play therapy and psychological support for the child and siblings. Ask what is available; good centres have all of it.

Where CureRays fits: radiation in children is a decision about the next sixty years, not the next six weeks. Where it is needed we plan it to protect growth and cognition — and where it can be avoided or reduced, that is the better answer and we will say so.

What the guidelines say

In broad strokes: treat at a children's cancer centre; assign a risk group using molecular testing and early treatment response; treat on a collaborative protocol or clinical trial where available; use radiation selectively and with growth- and cognition-sparing technique; discuss fertility preservation before treatment; and enrol every survivor in long-term follow-up.

Paediatric care in the U.S. is largely delivered through Children's Oncology Group protocols. Survivorship follow-up follows the Children's Oncology Group Long-Term Follow-Up Guidelines, which are freely available and genuinely worth a parent reading. Your team may also reference NCCN Guidelines for Patients®. The above is a plain-language overview, not the guidelines themselves.

Outcomes and odds of cure

Around 85% of children diagnosed with cancer today are alive five years later, up from roughly 63% in the mid-1970s — one of the largest sustained improvements in all of medicine.

That average hides real differences. Childhood ALL now exceeds 90% cure in many series. But brain and CNS tumours, bone tumours and sarcomas have lagged, with 5-year survival closer to 60%, and some — diffuse midline glioma in particular — remain very difficult. Brain tumours are now collectively the leading cause of childhood cancer death.

For context on the brain figures specifically, the NCI SEER childhood brain and other nervous system cancer page and the childhood leukemia page carry current figures by type.

We have deliberately not built a stage-by-stage table here, because childhood cancers use different risk-group systems rather than a common staging scale, and averaging them would mislead. Ask your child's oncologist for figures matched to the specific diagnosis and risk group — those are meaningful; the population average is not. Population statistics describe large groups, not individuals, and lag current treatment by years.

Side effects and how we watch for them

During treatment: low blood counts and infection risk (a fever in a child on chemotherapy is an emergency — go straight to the unit, do not wait), nausea, mouth sores, hair loss, fatigue, and the disruption of school and normal childhood. Steroids in leukemia treatment cause hunger, mood swings and sleeplessness that parents consistently find harder than expected — it is the drug, not your child.

Late effects are the other half of childhood cancer, and they deserve to be understood rather than feared:

• Heart — anthracyclines carry a lifetime cumulative dose; echocardiograms continue for decades.
• Hearing — cisplatin causes hearing loss; report changes immediately, as dose can be adjusted, and hearing loss in a young child affects language and schooling.
• Fertility — affected by some chemotherapy and by radiation. Preservation must be discussed before treatment.
• Growth and hormones — radiation near the pituitary, thyroid or growth plates affects height, puberty and thyroid function.
• Learning and cognition — cranial radiation and some chemotherapy can affect attention, processing speed and memory. Neuropsychological assessment and school support make a real difference and should be requested rather than waited for.
• Second cancers — a small but real long-term risk, which is why survivorship screening exists.

How it is assessed: graded at each visit, with organ-specific monitoring built into the protocol and continuing into adult life.

Follow-up, remission and survivorship

Remission means no detectable cancer. Follow-up is intensive at first, then gradually spaces out — but for childhood cancer survivors it never really stops, because the point shifts from watching for recurrence to watching for late effects.

Every childhood cancer survivor should have a written survivorship care plan listing exactly which drugs and doses were given, whether radiation was used and where, and what needs monitoring for life. Ask for it, keep it, and give a copy to every future doctor. Adult physicians frequently do not know what a patient received at age six, and that document is the single most useful thing a survivor can carry.

Transition to adult care is where survivors are most often lost, usually in the late teens or early twenties when they feel well and stop attending. That is exactly when long-term monitoring starts to matter. If you are a parent reading this years on: help your young adult stay connected to a survivorship clinic.

Siblings need attention too. Brothers and sisters of children with cancer carry a real and frequently unnoticed burden.

Questions parents actually ask

Informational only, not medical advice — confirm with your child's care team.

Talk with us about radiation in children

If radiation has been proposed for your child, we will explain honestly what it protects, what it risks, and whether it can be reduced or avoided.

Contact CureRays